These interactions, which influence targets associated with the cancer immune response, suggest that BJIKT enhances T cell function and TNF signaling and suppresses TGF-β signaling, leading to cell cycle arrest, apoptosis, and amplification of pembrolizumab’s anticancer effects. The gene discussed is TNF; the disease is cancer.